Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19BrN2.C4H4O4 |
Molecular Weight | 435.312 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C2=NC=CC=C2
InChI
InChIKey=SRGKFVAASLQVBO-DASCVMRKSA-N
InChI=1S/C16H19BrN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1
Molecular Formula | C16H19BrN2 |
Molecular Weight | 319.239 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DEXBROMPHENIRAMINE is an alkylamine derivative with anticholinergic and sedative properties. It is a histamine H1-receptor antagonist that competes with histamine for the H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. The antagonistic action of this agent blocks the activities of endogenous histamine, which subsequently leads to temporary relief from the negative histamine-mediated symptoms of an allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of the gastrointestinal smooth muscle. DEXBROMPHENIRAMINE as a part of combination medicine is used to treat symptoms of the common cold or seasonal allergies, including sneezing, runny or stuffy nose, and itchy, watery eyes.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PANATUSS PEDIATRIC DROPS DXP Approved UseUses:
- Temporarily relieves cough due to minor throat and bronchial irritations as may occur with the common cold;
- Temporarily relieves nasal congestions due to common cold;
- For temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or allergic rhinitis. Launch Date2005 |
|||
Palliative | PANATUSS PEDIATRIC DROPS DXP Approved UseUses:
- Temporarily relieves cough due to minor throat and bronchial irritations as may occur with the common cold;
- Temporarily relieves nasal congestions due to common cold;
- For temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or allergic rhinitis. Launch Date2005 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.98 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/ |
6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXBROMPHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
234.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/ |
6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXBROMPHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/ |
6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXBROMPHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
0.3 % 1 times / day steady, ophthalmic Recommended Dose: 0.3 %, 1 times / day Route: ophthalmic Route: steady Dose: 0.3 %, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
|
6 mg 4 times / day steady, oral Recommended Dose: 6 mg, 4 times / day Route: oral Route: steady Dose: 6 mg, 4 times / day Sources: |
healthy, adult |
PubMed
Title | Date | PubMed |
---|---|---|
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
Non-antibiotic treatments for upper-respiratory tract infections (common cold). | 2005 Dec |
|
Potentialities of ITP-CZE method with diode array detection for enantiomeric purity control of dexbrompheniramine in pharmaceuticals. | 2008 Apr 14 |
|
Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. | 2008 Dec |
|
Possibilities of column coupling electrophoresis provided with a fiber-based diode array detection in enantioselective analysis of drugs in pharmaceutical and clinical samples. | 2008 Jan 25 |
|
Acute cough: a diagnostic and therapeutic challenge. | 2009 Dec 16 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:33:48 GMT 2025
by
admin
on
Mon Mar 31 17:33:48 GMT 2025
|
Record UNII |
BPA9UT29BS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 341.12
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2391-03-9
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
C015121
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
219-236-2
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
DBSALT001411
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
SUB01626MIG
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
m2723
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
1178002
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
100000087764
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
BPA9UT29BS
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201287
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
C61706
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
6433334
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
BPA9UT29BS
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
48936
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID6047818
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
RACEMATE -> ENANTIOMER | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |